Completed PHASE4 INTERVENTIONAL 2-arm NCT02442817

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Sponsor: Augusta University

Interventions Linagliptin

Updated 6 times since 2017 Last updated: Nov 5, 2020 Started: Mar 2, 2015 Primary completion: Mar 2, 2018 Completion: Mar 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Augusta University and has accumulated 6 data snapshots since 2015. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2020 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Dec 2020 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Augusta University
University of Nevada, Reno

Data source: University of Nevada, Reno

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reno, United States